Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2015 May;35(5):449-59.
doi: 10.1016/j.nutres.2015.04.003. Epub 2015 Apr 11.

Lowering the dietary omega-6: omega-3 does not hinder nonalcoholic fatty-liver disease development in a murine model

Reilly T Enos  1 , Kandy T Velázquez  1 , Jamie L McClellan  1 , Taryn L Cranford  1 , Michael D Walla  2 , E Angela Murphy  3
Affiliations
Comparative Study

Lowering the dietary omega-6: omega-3 does not hinder nonalcoholic fatty-liver disease development in a murine model

Reilly T Enos et al. Nutr Res. 2015 May.

Abstract

It is hypothesized that a high dietary n-6:n-3 (eg, 10-20:1) is partly responsible for the rise in obesity and related health ailments. However, no tightly controlled studies using high-fat diets differing in the n-6:n-3 have tested this hypothesis. The aim of the study was to determine the role that the dietary n-6:n-3 plays in non-alcoholic fatty-liver disease (NAFLD) and colitis development. We hypothesized that reducing the dietary n-6:n-3 would hinder the development of NAFLD and colitis. Male C57BL/6 J mice were fed high-fat diets, differing in the n-6:n-3 (1:1, 5:1, 10:1, 20:1), for 20 weeks. Gas chromatography-mass spectrometry was used to analyze the hepatic phospholipid arachidonic acid (AA):eicosapentaenoic acid and AA:docosahexaenoic acid. Hepatic metabolism, inflammatory signaling, macrophage polarization, gene expression of inflammatory mediators, oxidative and endoplasmic reticulum stress, and oxidative capacity were assessed as well as colonic inflammatory signaling, and gene expression of inflammatory mediators and tight-junction proteins. Although reducing the dietary n-6:n-3 lowered the hepatic phospholipid AA:eicosapentaenoic acid and AA:docosahexaenoic acid in a dose-dependent manner and mildly influenced inflammatory signaling, it did not significantly attenuate NAFLD development. Furthermore, the onset of NAFLD was not paired to colitis development or changes in tight-junction protein gene expression. In conclusion, reducing the dietary n-6:n-3 did not attenuate NAFLD progression; nor is it likely that colitis, or gut permeability, plays a role in NAFLD initiation in this model.

Keywords: Colitis; High-fat diet; Murine model; Nonalcoholic fatty-liver disease; Omega-6:omega-3; α-Linolenic acid.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST STATEMENT

RTE, KTV, JLM, TLC, MDW, EAM do not have any conflicts of interest.

Figures

Figure 1
Figure 1
Impact of dietary n-6:n-3 on murine NAFLD development. (A) AA:EPA, and (B) AA:DHA in hepatic phospholipids, (C) liver weight, (D) hepatic lipid accumulation, (E) hepatic mRNA expression of metabolism-related genes, as well as (F) representative hepatic H&E (10x & 40x) and oil red O images (20x) displaying steatosis and inflammatory infiltrate (n=10/group). Scale bars represent 200 µm. Treatment groups included a control diet (AIN-76A Mod) and four HFDs differing in the n-6:n-3 (1:1, 5:1, 10:1, and 20:1) consumed for a 20-week period. Diets not sharing a common letter differ significantly from one another (P≤.05). Data are presented as means (±SEM).
Figure 2
Figure 2
Representative hepatic western blots for markers of (A) inflammatory signaling, as well as gene expression of (B) macrophage and (C) inflammatory markers (n=10/group). Treatment groups included a control diet (AIN-76A Mod) and four HFDs differing in the n-6:n-3 (1:1, 5:1, 10:1, and 20:1) consumed for a 20-week period. All western blots were run under the same experimental conditions. Diets not sharing a common letter differ significantly from one another (P≤.05). Data are presented as means (±SEM).
Figure 3
Figure 3
Representative hepatic western blots for markers of (A) oxidative stress, (B) ER stress, and (C) oxidative capacity (n=10/group). All western blots were run under the same experimental conditions. Treatment groups included a control diet (AIN-76A Mod) and four HFDs differing in the n-6:n-3 (1:1, 5:1, 10:1, and 20:1) consumed for a 20-week period. Diets not sharing a common letter differ significantly from one another (P≤.05). Data are presented as means (±SEM).
Figure 4
Figure 4
Representative colonic western blots for markers of (A) inflammatory signaling, gene expression of (B) inflammatory and (C) tight-junction markers, as well as (D) representative colonic H&E images (20x) (n=10/group). All western blots were run under the same experimental conditions. Scale bars represent 200 µm. Treatment groups included a control diet (AIN-76A Mod) and four HFDs differing in the n-6:n-3 (1:1, 5:1, 10:1, and 20:1) consumed for a 20-week period. Diets not sharing a common letter differ significantly from one another (P≤.05). Data are presented as means (±SEM).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of nonalcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–285. - PubMed
    1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592–1609. - PubMed
    1. Leamy AK, Egnatchik RA, Young JD. Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Prog Lipid Res. 2012 - PMC - PubMed
    1. Yeh MM, Brunt EM. Pathological features of fatty liver disease. Gastroenterology. 2014;147:754–764. - PubMed
    1. Chassaing B, Etienne-Mesmin L, Gewirtz AT. Microbiota-liver axis in hepatic disease. Hepatology. 2014;59:328–339. - PMC - PubMed

Publication types

MeSH terms